Key result
Ultrashort DAPT did not increase MACCE risk and reduced major bleeding compared to standard-duration DAPT.
Why the study?
The efficacy and safety of ultrashort (<=1-month) DAPT followed by antiplatelet monotherapy remain uncertain in ACS patients.
Meta-Analysis (n=29,232)
Answers are grounded in this paper and cite their sources.
Background The efficacy and safety of ultrashort (≤1-month) dual antiplatelet therapy (DAPT) followed by antiplatelet monotherapy remain uncertain in acute coronary syndrome (ACS) patients. Objectives This study sought to compare ultrashort vs standard-duration DAPT in patients with ACS undergoing percutaneous coronary intervention (PCI). Methods We conducted a systematic review and meta-analysis of randomized controlled trials until February 15, 2026. Primary outcomes were major adverse cardiac and cerebrovascular events (MACCE), major bleeding, and net adverse clinical event (NACE). Prespecified subgroup analyses examined by ethnicity (East Asian vs non-East Asian) and abbreviation strategy (intensive: ≤1-week DAPT or clopidogrel/aspirin monotherapy vs moderate: ≥2-week DAPT, followed by ticagrelor/prasugrel monotherapy). Results Across 10 trials (n = 29,232), ultrashort DAPT did not increase MACCE risk (HR: 1.06; 95% CI: 0.93-1.20; *P* = 0.38; *I* 2 = 24%), with higher MACCE risk observed in ST-segment elevation myocardial infarction (STEMI) but not non-ST-segment elevation ACS (NSTE-ACS), and significantly reduced major bleeding (HR: 0.47; 95% CI: 0.35-0.64; *P* < 0.00001; *I* 2 = 44%), resulting in a net clinical benefit (HR: 0.83; 95% CI: 0.72-0.97; *P* = 0.02; *I* 2 = 61%). Bleeding reduction was more pronounced in East Asians (HR: 0.35; 95% CI: 0.25-0.49; *P* < 0.00001; *I* 2 = 0%) than non-East Asians (HR: 0.63; 95% CI: 0.43-0.93; *P* = 0.02; *I* 2 = 44%), with a significant interaction ( *P* = 0.02). The abbreviation strategy significantly modified outcomes ( *P* for interaction = 0.003): intensive abbreviation raised MACCE risk (HR: 1.37; 95% CI: 1.11-1.69; *P* = 0.003; *I* 2 = 0%), while moderate abbreviation had no statistically significant difference (HR: 0.96; 95% CI: 0.85-1.08; *P* = 0.47; *I* 2 = 0%). Conclusions In patients with ACS undergoing PCI, ultrashort DAPT reduced bleeding without increasing ischemic events overall, although a signal of increased MACCE was observed in STEMI but not in NSTE-ACS. Bleeding reduction was greater in East Asians, while ≤1-week DAPT or clopidogrel/aspirin monotherapy may increase ischemic risk.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) conducted a meta-analysis in Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (n=29,232). Ultrashort (≤1-month) dual antiplatelet therapy (DAPT) vs. Standard-duration DAPT was evaluated on Major adverse cardiac and cerebrovascular events (MACCE) (HR 1.06, 95% CI 0.93-1.20, p=0.38). Ultrashort DAPT did not increase MACCE risk and reduced major bleeding compared to standard-duration DAPT.
Synapse has enriched 10 related papers. Consider them for comparative context: